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Abstract 
Objective 
Chronic hepatitis C (HCV) infection is associated with diabetes and favourable lipids.  We studied the 
effect of this paradox on atherosclerosis and cardiometabolic response to HCV clearance.   
 
Design 
Cross-sectional study. 
 
Setting 
Egypt. 
 
Participants 
329 chronically infected, 173 with cleared infection, and 795 never infected participants aged ≥35 
attended for baseline investigations.  A subsample of 192, 115, and 187 respectively underwent 
ultrasound. 
 
Main outcome measures 
Diabetes, fasting glucose, lipids and fat deposition on ultrasound.  Carotid intima media thickness 
(IMT) measured atherosclerosis. 
 
Results 
Diabetes prevalence was elevated (10.1% (95% CI 6.6,13.6), p=0.04) in HCV chronic, and cleared 
(10.1% (5.6,14.8), p=0.08) individuals versus 6.6% (4.9,8.3) in those never infected.  Mesenteric fat 
was elevated in chronic (36.4 mm (34.5,38.2)), p=0.004, and cleared infection (37.8 (35.6,40.0)), 
p<0.0001 versus never infected (32.7 (31.0,34.4)).  LDL cholesterol was lower in chronic (2.69 
mmol/l (2.53,2.86) p<0.001), but similar in cleared (3.56 (3.34,3.78) p=0.4) versus never infected 
(3.45 (3.30,3.60)).  Carotid IMT did not differ by infection status (0.73 (0.70,0.76, p=0.4), 0.71 
(0.66,0.75), p=0.9), 0.71 (0.68,0.74) respectively.  Adjustment for cardiovascular risk factors elevated 
IMT in chronic infection (0.76 (0.72,0.79) p=0.02), versus never infected individuals (0.70 
(0.67,0.73)). 
 
Conclusions 
Hepatic function normalisation with HCV clearance may account for reversal of favourable lipids 
observed with HCV infection.  Hyperglycaemia and visceral adiposity appear less amenable to HCV 
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resolution.  These different cardiovascular risk patterns may determine equivalent atherosclerosis risk 
by infection status.  However, once these factors were accounted for, those with chronic infection had 
elevated IMT, suggesting a direct effect of infection.  
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Summary 
 
What is known about this subject? 
1. Chronic HCV infection is associated with an elevated prevalence of diabetes and insulin 
resistance, yet lipid profiles are favourable, compared to people never infected with HCV. 
2. Reports of the effect of this paradoxical risk factor profile on atherosclerosis are conflicting, 
due to limitations of previous study designs, either due to biased sampling, or lack of power.   
3. The effect of HCV clearance on both diabetes and lipid profiles and downstream effect on 
atherosclerosis has not been studied. 
 
What are the new findings? 
1. Chronic HCV infection is associated with central fat deposition on ultrasound, in addition to 
the known elevated risk of diabetes and insulin resistance. 
2. Atherosclerosis, as measured by intima media thickness (IMT) on carotid ultrasound was not 
elevated in those with chronic infection. 
3. However, multivariate adjustment for cardiovascular risk factors revealed an elevated IMT 
in those with chronic infection, indicative of a direct effect of infection on atherosclerosis, 
masked by the effect of favourable lipid profiles. 
4. Clearance of HCV infection was associated with reversal of favourable lipid profiles to those 
observed in never infected individuals.  However, diabetes prevalence, and central obesity, 
remained elevated.  No impact on carotid IMT was observed.  
 
How might these findings impact on clinical practice? 
1. As the developing world faces an epidemic of diabetes, consideration should be given to 
screening those with chronic or cleared HCV infection for early signs of diabetes, which 
should be managed accordingly. 
2. Our findings provide reassurance that changes in cardiovascular risk factors in association 
with HCV infection do not result in elevated risks of atherosclerosis.   
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Introduction 
The developing world now faces the double burden of escalating rates of chronic, non-communicable 
disease on the background of endemic infection1.  Important biological interactions may occur 
between these two groups of superficially unrelated conditions, specifically, cardiovascular disease 
(CVD) risk may be increased by infection2.  Hepatitis C virus (HCV) infection is common in many 
parts of the developing world, and is associated with a 3.5 fold increased prevalence, and an over 10 
fold increased incidence of type 2 diabetes3-5.  This is likely to be a consequence of insulin 
resistance6.  However, unlike the classical form of insulin resistance, chronic HCV infection is 
associated with a favourable lipoprotein profile7;8, specifically reduced levels of apolipoprotein B 
(apoB)-containing lipoproteins, such as LDL and VLDL cholesterol9.   
 
The consequence of this discordance between elevated diabetes prevalence, yet favourable 
lipoproteins, on CVD risk is unclear, but important to understand as CVD is now the major cause of 
death and disability worldwide.  A single report indicates rates of coronary disease are elevated by 
25% in those with chronic HCV infection10. But the more numerous studies measuring carotid intima 
media thickness (IMT), a valid proxy of atherosclerosis and future CVD risk11 have been 
conflicting12-15.  Discrepancies between studies are likely to be due to inadequacies in study design; 
for example, biased study population selection12, small numbers13, combining  hepatitis C and B15, 
and biased comparator groups13, with inadequate adjustment for confounders.  Further, no study has 
fully explored the impact of clearance of HCV, either spontaneously or with treatment, on 
cardiometabolic risk. 
 
Egypt has the highest HCV prevalence in the world (12% prevalence of HCV antibody in the general 
population, 40% in persons over age 40 in rural areas)16, and is a population that is susceptible to both 
diabetes and CVD.  Egypt therefore is an ideal setting for a population based study, reducing biases 
introduced by studying selected clinic populations, and being more generalisable.  Our aims were: 
1.  To confirm that chronic HCV infection is associated with both hyperglycaemia and a favourable 
lipoprotein profile compared to those never infected. 
2.  To determine how other aspects of the metabolic syndrome, specifically body fat distribution, 
blood pressure and insulin, differ by HCV infection status. 
3.  To compare carotid IMT, a measure of subclinical atherosclerosis, by HCV infection status, and 
explore the role of risk factors on IMT.   
4.  To determine the effect of HCV clearance on cardiometabolic risk. 
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Methods 
Sample population 
Our study sampled from the village of Zawyat Razin, 200 miles from Cairo.  A cohort study of the 
natural history of HCV was established in 2002.  This recruited 4020 participants aged 3 to 88 years 
out of a total 5130 identified from a nominated sector of the village17.  Of these 4020 individuals, 
1143 were aged 35 years and above at the time of this study (199 with chronic HCV infection 
(positive anti-HCV antibodies and positive RNA), 127 with spontaneously cleared infection (positive 
anti-HCV antibodies and negative RNA) and 817 never infected by HCV (negative anti-HCV 
antibodies)).  As risks of both diabetes and atherosclerosis increase with age, we chose to study adults 
only as we wished to be certain of detecting differences in cardiometabolic measures by infection 
group should they exist.  To achieve the required sample size for the clinic study (see below), 
sampling was extended to the 845 individuals aged 35 years and above in a neighbouring sector of the 
village, who had participated in a voluntary HCV testing programme also in 2002 (208 with chronic 
HCV infection, 120 with spontaneously cleared infection, and 517 never infected).  Disease 
distribution in the voluntary testing programme was similar to that in the HCV cohort study.  This 
yielded a total sample population of 1988.   
 
Village metabolic study 
These 1988 individuals were invited to take part in the village metabolic study.  After informed 
consent, a questionnaire collecting demographic, medical and lifestyle data was administered, and the 
following measurements were performed: height and weight, waist (midway between the umbilicus 
and anterior superior iliac spine) and hip (at the level of the greater trochanter) circumference, seated 
blood pressure calculated as the average of three measurement after 10 minutes rest using a validated 
oscillometric device (Omron 705CP), and fasting blood samples were collected for measurement of 
glucose and lipid profiles.  These samples were sent to Cairo on a daily basis for analysis.   
 
Clinic cardiometabolic study 
All those attending the village metabolic study were eligible for a detailed clinic examination for 
cardiometabolic status at the National Hepatology and Tropical Medicine Research Institute in Cairo. 
The target was 210 attendees each in the chronic, cleared and never infected categories.  The three 
infection status groups were stratified into 5 year age bands, and similar numbers of individuals from 
each band for those with chronic or cleared infection (where numbers were most limited) were first 
invited to the clinic.  We had hoped to match by sex in each age stratum but numbers in each cell 
were too limited.  Recruitment for those with chronic infection was completed first, and numbers in 
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requisite age strata for cleared infection were exhausted at 135 recruits.  Recruiting beyond this 
number would have seriously unmatched the age distribution of this group, making analysis difficult.  
Substantially more of those never infected agreed to participate than required, so transfer to the clinic 
study was stopped when the requisite sample was completed.  
 
During the Cairo clinic visit anthropometric measurements (weight and height, waist and hip 
circumference) were again performed, and in addition, measurement of bioimpedence for total 
percentage of body fat (Tanita TBF-300M), and abdominal ultrasound using a Siemens Energia 
machine, to assess regional fat distribution, specifically mesenteric, (3-5 MHz curved transducer in 
the para-umbilical area, to identify mesenteric leaves, calculating the mean of the thickest 3 leaves) 
and abdominal subcutaneous fat (linear 7-12 MHZ transducer at L5, again the mean of 3 measures 
taken of the maximum thickness), all as previously described18. Clinic sitting blood pressure was 
again measured using a validated oscillometric device (Omron 705CP).  
 
Carotid ultrasound measurements with concurrent ECG recording were performed using a Philips 
HDI ATL 5000 ultrasound machine equipped with a linear array broad band 7-4 MHz transducer. 
Carotid IMT was measured in the far wall of the left common carotid artery (CCA) and carotid bulb19.  
B mode images were saved as cineloops and measurement of IMT and lumen diameter was 
performed off-line from images acquired in diastole (identified by the ECG R wave) using a validated 
semiautomatic program20.  Atherosclerotic plaques (defined as focal thickenings of the intima-media 
>1.3mm or a distinct area with an IMT >50% thicker than the adjacent region) were imaged using B 
mode ultrasound using colour or power Doppler to assist visualization if necessary. A single observer 
made all ultrasound measurements blinded to patient status. 
 
A 30 ml fasting blood sample was drawn, and sent locally for measurement of AST, ALT, γGT, 
albumin, total bilirubin, lipid profile (fasting serum cholesterol, HDL cholesterol, triglycerides, LDL 
(Friedewald method)) and glucose, all using standard methods on a Beckman Synchron CX4 Clinical 
Analyser (Beckman Instruments, Brea, CA, USA).  Insulin was determined using AxSYM Insulin 
Assay (Abbott Laboratories, Wiesbaden Germany), and C-peptide was determined using DRG C-
peptide ELISA kit (Marburg, Germany) according to manufacturer instructions. The diagnosis of 
HCV infection was confirmed by serology testing using an Elisa (INNOTEST® HCV Ab IV, 
Innogenetics, Ghent, Belgium) and, when positive, confirmed by Abbott HCV EIA 3.0 (Abbott 
Laboratories, Diagnostics Division, IL, USA). Molecular identification of HCV RNA was performed 
using a one-step reverse transcriptase-polymerase chain reaction (RT-PCR) assay. Individuals testing 
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positive by the two serological tests and PCR positive were considered as HCV positive, with chronic 
infection if HCV RNA was positive.  Individuals with negative serological results were considered as 
never infected by HCV. 
 
Sample size and statistical analysis  
The main study outcome was mean carotid IMT.  We required 190 participants per group to show a 
standardised difference of 0.29 between those with chronic versus no HCV infection (alpha=0.05, 
power=0.8, two-sided tests).  This means that if we assume a population standard deviation in carotid 
IMT of 0.18 mm, we could detect a difference in mean IMT between infection groups of at least 0.05 
mm.  No study has reported mean values of carotid IMT between those with and without HCV, 
although a nearly 3 fold increase in risk of IMT thickening above a given cutpoint has been 
reported12.  Previous studies of the association between IMT and the presence or absence of 
chlamydia pneumoniae report a standardised difference of 0.4021.  We wished to ensure that a 
difference of at least this magnitude could be detected here, and settled for the more conservative 
effect of 0.29, anything larger could then be detected with much greater power.  A total of 210 
attendees in each group were required to allow for missing data. 
 
Variables not normally distributed were log transformed for analysis.  Mean values for normally 
distributed and transformed data, with 95% confidence limits, were estimated using regression 
analysis.  As the comparison groups differed in age and sex distribution, age and sex adjusted values 
are presented throughout although in practice this made modest differences to the estimates.  For 
categorical variables, direct standardization for age and sex was performed, using the total study 
population (be it at the village or in the Cairo clinic), as the standard.  Pearson (for normally 
distributed data), and Spearman (for non-parametric data) correlation coefficients between key 
variables were estimated.  Multivariate regression analysis for continuous variables was performed 
using analysis of co-variance, and for categorical variables logistic regression, with adjustment for 
variables that biologically were thought to act as confounders.  Age and sex were forced into these 
models.  Thus any residual differences between infection categories are unlikely to be due to 
imbalances in the key immutable characteristics of age and sex, allowing us to focus on reversible 
risk factors and provide insights into mechanisms.   
 
The ADA definition of diabetes was used22.  Hypertension was defined as either being on self 
reported medication for hypertension, or systolic pressure ≥140 mmHg, or diastolic pressure ≥ 90 
mmHg. 
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Results 
Village study of diabetes prevalence and lipid profiles 
A total of 795 (60% response rate) people who had never been infected with HCV, 173 (70% 
response rate) with cleared infection, and 329 (81% response rate) with chronic infection were 
examined in the village (overall 65% response rate).  Those with chronic infection or cleared 
infection were older and more likely to be male than those never infected (table 1).  However those 
with chronic infection, although lighter, had elevated fasting glucose, and elevated prevalence of 
diabetes (odds ratio 1.31, 95% CI 1.03,1.66, p=0.03, adjusted for age and sex) than never infected 
individuals.  Further adjustment for BMI did not alter this excess risk (odds ratio 1.35, 95% CI 
1.06,1.73, p=0.02).  In contrast, lipid profiles in those with chronic infection were favourable, with 
lower total and LDL cholesterol, and lower triglyceride.   
 
Clearance of infection was associated with persistent elevation of diabetes prevalence, but a fasting 
glucose that was midway between those never infected and those with chronic infection.  Weight, 
lipid and lipoprotein profiles are similar to those observed in never infected individuals.      
 
Clinic study of IMT and fat imaging  
A subgroup of 227 never infected individuals, 135 with cleared infection, and 207 with chronic 
infection attended the clinic in Cairo for IMT scans.  All those with cleared and chronic infection 
studied in the village were invited to yield sufficient numbers, a response rate of 78% and 63% 
respectively.  Quota sampling was used to obtain the 227 who had never been infected, as many more 
volunteered than were required in this category.  
 
Analysable IMT data were successfully obtained on 192 never infected, 115 with cleared infection, 
and 187 with chronic infection (missing data was due to limited access to equipment, equipment 
breakdown, and scans of insufficient quality).  Differences observed in the village population in 
demographic and metabolic characteristics by infection status were also observed in the clinic sample, 
although some of the associations did not reach statistical significance (table 2).  For example, the 
odds ratio for diabetes comparing chronic with never infected individuals, at 1.26, was similar to that 
observed in the village, but was not statistically significant due to the smaller numbers studied here 
((95% CI 0.82,1.95), p=0.3 adjusted for age and sex).  Among the additional measurements made in 
the clinic, fasting insulin and HOMA-IR were both significantly higher in those with chronic 
infection than in those never infected or those with cleared infection. 
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BMI, and total %fat were lower in those with chronic infection, than in those with cleared or no 
infection.  Although no differences in waist to hip ratio by infection status were observed, mesenteric 
fat levels were elevated in those with chronic infection, whilst subcutaneous fat levels were reduced, 
compared to those never infected.   Clearance of infection was associated with BMI and fat% 
equivalent to that of never infected individuals, whilst mesenteric fat remained elevated. 
 
Age and sex adjusted mean carotid IMT and proportion of individuals with carotid plaque did not 
differ significantly by infection status (table 3).  Adjusting for all CVD risk factors, whether 
favourable or not, resulted in a carotid IMT, and burden of plaque, that was now significantly higher 
in those with chronic versus never infection.  For plaque, it should be noted that numbers were small, 
resulting in instability of estimates when subject to multivariate adjustment.  The major contributors 
to the multivariate model for IMT were LDL cholesterol (p=0.002), and systolic blood pressure 
(p=0.008).   
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Discussion 
We confirm that people with chronic HCV infection have an elevated prevalence of diabetes, are 
more likely to be hyperglycaemic, and insulin resistant, compared to those who were never infected, 
even though they are on average lighter with less total fat mass.  Despite the insulin resistance, lipid 
and lipoprotein profiles are favourable.  Novel findings from this study include the observation that 
chronic infection is associated with central fat deposition, and loss of subcutaneous fat.  Secondly, we 
show that clearance of infection was associated with resolution of lipid and lipoprotein profiles, and 
total weight approximating never infected individuals, but persistent, albeit non-significant elevations 
in glucose and diabetes prevalence, and persistence of central fat deposition.  Thirdly, we demonstrate 
that carotid IMT, a measure of subclinical atherosclerosis, did not differ significantly by infection 
status.  Adjustment for conventional CVD risk factors, particularly LDL cholesterol and systolic 
blood pressure, resulted in an IMT in those with chronic infection that was significantly elevated 
compared to those never infected.  Findings for carotid plaque, although numbers were small, 
confirmed those for mean IMT.  This may suggest a direct effect of infection on atherosclerosis. 
 
We show that diabetes risk is elevated by about a third in association with chronic HCV infection.  
Previous studies report much greater risks, but have important limitations which may exaggerate 
risks.  These include restriction of HCV cases to those with cirrhotic disease5, small numbers3, a 
comparator population made up of cases with hepatitis B and other liver disorders23, or a healthy 
population sample drawn from a very different source to cases24.  In many countries, HCV infection is 
commonly associated with drug abuse; to draw a comparison with individuals participating in 
national health surveys, or attending clinics and hospitals for other reasons, is vulnerable to bias.  
Others have matched cases (with HCV) and controls (without HCV) for a number of risk factors, 
including obesity25.  According to our data, people with chronic HCV in the population are lean, thus 
matching for obesity status will result in recruiting very lean individuals from the control population, 
who would have very low risks of diabetes, thus exaggerating the risk of diabetes associated with 
infection.  Interestingly, reports of comparisons within a healthy population based health survey have 
been conflicting, with one reporting an increased prevalence of diabetes associated with HCV4, and 
the other not26.  As the HCV epidemic in Egypt is to some extent a consequence of a population wide 
schistosomiasis treatment programme undertaken in the 1960s, sampling from a village population, 
who were all exposed to identical conditions, is a more optimal sampling strategy. 
 
Despite diabetes and insulin resistance, we confirm the very specific lipid and lipoprotein profile in 
chronic HCV infection, predominantly affecting total and LDL cholesterol9;26.  Derangements in lipid 
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metabolism have been proposed to be due to a variety of mechanisms including impaired assembly 
and secretion of VLDL as a consequence of the effect of HCV core protein on microsomal transfer 
protein, alterations in the composition of VLDL, and alterations in VLDL and LDL catabolism27;28.  
All these effects occur in the liver, thus clearance of HCV infection, which resolves hepatic damage, 
should also resolve the lipoprotein changes.  This is what we see in the group of individuals who had 
cleared their infection.  That resolution of HCV, and presumably to some extent liver damage, does 
not affect diabetes prevalence or unfavourable ectopic fat distribution, and does not wholly reduce the 
hyperglycaemia associated with chronic infection, suggests that other mechanisms are involved in 
these changes, or that these effects of infection are resistant to change.  In the case of diabetes itself, it 
is likely that once an individual has this diagnostic label they are unlikely to lose it even if glucose 
levels return to normal, thus prevalence estimates will often lag behind actual changes in glucose.  Of 
course glycaemic and lipoprotein profiles are influenced by lifestyle factors such as diet and exercise, 
and we do not have precise measures of these to determine their role.  Yet whilst these lifestyle 
factors may differ by infection status, it would be hard to hypothesise a dietary and exercise pattern 
that results in diabetes on the one hand, yet favourable lipoprotein patterns on the other.  Thus we do 
not believe our findings are due to residual confounding.  These metabolic changes were observed in 
individuals who cleared infection spontaneously; data on the impact of antiviral therapy on metabolic 
characteristics are conflicting, and require further investigation29;30 
 
Our second novel finding, that chronic HCV infection is associated with low total body fat, but 
increased deposition of fat around the viscera, whilst subcutaneous fat deposition is reduced, is 
consistent with the greater degree of insulin resistance and diabetes in this group, but somewhat at 
odds with previous studies, although many matched for obesity status so these previous comparisons 
are prone to bias.  Studies unmatched for obesity however suggest that HCV patients are more obese 
overall, and had greater waist circumferences than controls31.  However controls in this case were 
selected from hospital staff members and relatives, and again, are not representative of the source 
population of cases.  An analysis of a population based health survey (where clearly cases will come 
from the same source population as non-cases) does support our finding of less obesity, and narrower 
waist circumference in the presence of chronic infection, at least in those aged 20-59 years26.  A 
narrower waist circumference in tandem with ultrasound evidence of visceral fat deposition is not 
inconsistent, as waist circumference includes both visceral and subcutaneous fat.  As subcutaneous fat 
levels are lower in those with chronic infection, it is likely that loss from this fat depot contributes to 
the lower waist circumference. 
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Our finding of carotid IMT levels that did not differ significantly by infection status is again in 
contrast to some previous reports.  Again there are concerns regarding the comparisons made in 
previous studies, with controls recruited from hospital staff31, cases being a mixture of individuals 
with hepatitis B and C15, and comparisons made between angiography patients with and without 
diagnosed coronary disease13.  A comparison within a group attending for health screening found 
markedly more plaque (IMT >1.3mm) and more carotid intima-medial thickening (IMT ≥ 1mm) in 
those who were HCV positive, but these individuals were on average 4 years older than non-infected 
persons, and mean carotid IMT, (our key outcome), did not differ significantly12;32.   
 
We conclude that hyperglycaemia and insulin resistance on the one hand, and a favourable lipid and 
lipoprotein profile on the other, results in a degree of atherosclerosis in people with chronic HCV 
infection that is no different to those never infected.  We could not measure an emerging important 
component of the metabolic syndrome, non-alcoholic fatty liver disease (NAFLD), which is a strong 
independent predictor of cardiovascular disease33, as this would have required biopsy for accuracy.  
However, given the different balance of existing risk factors associated with NAFLD, it is unclear 
whether its prevalence would be higher, lower or about the same in those with chronic HCV infection 
versus those never infected.  An elevated IMT in those with chronic infection emerges when 
accounting for CVD risk factors, suggesting that there may be a direct effect of infection on 
subclinical atherosclerosis.  This observation confirms the single large report of an elevated risk of 
coronary events in those with chronic infection10, only noted on multivariate adjustment, even though 
individuals with chronic HCV had a generally more favourable CVD risk factor profile, forcing the 
authors to conclude that excess CVD risk in those with chronic HCV infection must occur by non-
conventional pathways, associated with the infection itself.  Clearance of infection returns lipoprotein 
profiles to normal levels, perhaps as a consequence of resolution of liver damage, but does not 
remove the excess diabetes risk, nor the central fat deposition, suggesting that mechanisms for these 
disturbances are different, or that they are less amenable to reversal as a consequence of treatment.  
Although we show no excess carotid IMT in these individuals, long term follow up data are required 
to determine the impact of infection clearance on atherosclerosis, particularly given the reversal of 
favourable lipoprotein profiles.  As the burden of CVD increases in these populations, and as attempts 
focus on treating HCV infection worldwide, this question requires urgent attention.   
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Table 1. Demographic and metabolic characteristics by infection status of individuals studied in the village. 
 Never infected (n = 795) Cleared infection (n = 173) Chronic infection (n=329) 
Variable Mean or % 95% CI Mean or % 95% CI p value Mean or % 95% CI p value
Age (years) 49.4 48.6,50.1 51.4 49.9,52.9 0.01 51.0 50.0,51.9 0.01
Male % (n) 37 (295) 49 (85)  0.003 59 (195) <0.0001
BMI, kg/m2 29.4 29.0,29.8 29.5 28.6,30.3 0.8 28.0 27.4,28.6 <0.0001
Waist hip ratio (men) 0.91 0.90,0.92 0.92 0.91,0.94 0.3 0.92 0.91,0.93 0.6
Waist hip ratio (women) 0.87 0.86,0.88 0.86 0.85,0.88 0.2 0.87 0.86,0.88 0.4
SBP, mmHg 123 121,124 120 117,123 0.07 121 118,123 0.08
DBP, mmHg 75 74,76 73 71,75 0.05 74 73,75 0.3
Total cholesterol, mmol/l 5.19 5.11,5.28 5.16 4.98,5.34 0.8 4.33 4.20,4.46 <0.0001
LDL-cholesterol, mmol/l 3.40 3.32,3.47 3.43 3.25,3.60 0.8 2.67 2.55,2.80 <0.0001
HDL-cholesterol, mmol/l 1.24 1.20,1.28 1.16 1.07,1.26 0.2 1.18 1.11,1.25 0.2
Triglyceride, mmol/l* 1.10 1.06,1.15 1.16 1.06,1.26 0.4 0.97 0.91,1.03 0.001
Glucose, mmol/l* 4.83 4.74,4.90 4.95 4.76,5.15 0.3 5.05 4.90,5.20 0.009
Albumin, g/l 38.3 38.0,38.6 38.3 37.7,39.0 0.9 37.7 37.2,38.1 0.02
ALT, IU/L* 19.6 19.0,20.3 19.1 17.8,20.4 0.5 35.5 33.8,37.3 <0.0001
AST, IU/L* 20.3 19.6,20.9 20.4 19.1,21.8 0.8 36.7 34.8, 38.5 <0.0001
γGT,IU/L* 26.8 23.1,31.2 22.2 18.2,27.1 0.1 27.1 22.2,32.3 0.9
Total bilirubin, µmol/l* 10.1 9.8,10.4 10.9 10.2,11.7 0.05 12.8 12.1,13.4 <0.0001
Diabetes 6.6 4.9,8.3 10.1 5.6,14.8 0.08 10.1 6.6,13.6 0.04
Hypertension 14.3 11.9,16.8 17.2 11.8,22.5 0.3 17.2 12.8,21.5 0.2
Current smoker 8.7 6.7,10.7 8.9 4.4,13.4 1.0 11.1 7.7,14.7 0.2
Apart from age and sex themselves, all other parameters are adjusted (continuous) or standardised (categorical) for age and sex (except waist hip 
ratio, where age adjusted values are presented stratified by sex).  P values comparing either cleared, or chronic infection, with no infection. 
*Log transformed variable, geometric means reported. 
Abbreviations: ALT, alanine aminotransferase; AST, Aspartate aminotransferase, BMI, body mass index; DBP, diastolic blood pressure; γGT, 
Gamma-glutamyl transpeptidase; HDL, high density lipoprotein; LDL, low density lipoprotein; SBP, systolic blood pressure.  
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Table 2. Demographic and metabolic characteristics by infection status of individuals studied in the clinic. 
 Never infected (n = 192) Cleared infection (n = 115) Chronic infection (n=187) 
Variable Mean or % 95% CI Mean or % 95% CI p value Mean or % 95% CI p value
Age (years) 50.2 48.6,51.7 51.0 49.3,52.7 0.5 50.8 49.7,51.9 0.5
Male % (n) 45 (87) 51 (59)  0.3 63 (118) 0.001
BMI, kg/m2 29.1 28.3,29.9 28.9 27.9,29.9 0.8 27.7 26.9,28.5 0.01
Fat % 30.6 29.5,31.7 30.5 29.1,31.9 0.9 29.1 28.0,30.2 0.05
Waist hip ratio (men) 0.91 0.90,0.93 0.92 0.90,0.94 0.6 0.92 0.90,0.93 0.7
Waist hip ratio (women) 0.88 0.87,0.89 0.86 0.85,0.88 0.2 0.86 0.84,0.88 0.09
Mesenteric fat (mm) 32.7 31.0,34.4 37.8 35.6,40.0 <0.0001 36.4 34.5,38.2 0.004
Subcutaneous fat (mm) 12.4 11.8,13.0 11.5 10.8,12.3 0.08 11.1 10.4,11.7 0.004
SBP, mmHg 122 119,125 119 115,122 0.1 119 116,122 0.1
DBP, mmHg 76 74,77 72 70,75 0.03 74 72,75 0.1
Total cholesterol, mmol/l 5.16 5.00,5.32 5.28 5.06,5.50 0.4 4.36 4.20,4.53 <0.0001
LDL-cholesterol, mmol/l 3.45 3.30,3.60 3.56 3.34,3.78 0.4 2.69 2.53,2.86 <0.0001
Glucose, mmol/l* 4.83 4.68,4.99 4.95 4.76,5.19 0.3 5.01 4.86,5.48 0.2
Insulin µIU/ml* 4.00 3.42,4.66 3.99 3.24,4.91 0.9 5.81 4.85,6.95 0.004
HOMA-IR* 0.50 0.42,0.60 0.50 0.40,0.63 1.0 0.73 0.60,0.89 0.005
HOMA-S* 198 167,237 200 159,252 1.0 137 112,167 0.005
HOMA-B* 59 52,67 57 48,68 0.8 73 63,86 0.04
C-peptide 1.26 1.07,1.48 1.43 1.13,1.80 0.4 1.31 1.09,1.57 0.7
AST, IU/L* 21.8 20.4,23.2 20.9 19.3,22.8 0.5 35.1 32.8, 33.3 <0.0001
Diabetes 4.6 1.8,7.5 9.6 4.0,14.2 0.1 7.0 3.3,11.1 0.4
Hypertension 21.0 15.3,26.7 15.7 9.8,21.6 0.3 16.2 11.0,21.5 0.2
Current smoker 5.8 2.6,9.1 9.6 4.4,14.9 0.2 14.2 9.1,19.2 0.005
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Apart from age and sex themselves, all other parameters are adjusted (continuous) or standardised (categorical) for age and sex (except waist hip 
ratio, where age adjusted values are presented stratified by sex). 
*Log transformed variable. 
Abbreviations: AST, Aspartate aminotransferase, BMI, body mass index; DBP, diastolic blood pressure; LDL, low density lipoprotein; SBP, 
systolic blood pressure.  
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Table 3.  Mean carotid IMT (mm), and burden of carotid plaque by infection status 
 
 
 Never infected (192) Cleared infection (115) 
p 
value
Chronic infection 
(187) p value 
Carotid IMT (mm)  Mean 95% CI Mean 95% CI  Mean 95% CI  
Adjusted for age and sex 0.71 0.68, 0.74 0.71 0.66, 0.75 0.9 0.73 0.70, 0.76 0.4 
Fully adjusted 0.70 0.67, 0.73 0.69 0.65, 0.74 0.8 0.76 0.72, 0.79 0.03 
      
Carotid plaque        
N (%) 10 (5.2%)  4 (3.5%)   12 (6.4%)   
Odds ratio, adjusted for 
age and sex 1.00  0.64 0.21,1.98 0.4 1.88 0.77,4.56 0.2 
Odds ratio, fully adjusted 1.00  0.32 0.06,1.64 0.2 3.49 1.22,9.97 0.02 
 
 
 
P values compare either cleared or chronic infection group with never infected.   
Comparisons of odds ratios for plaque use the never infected group as the comparator (odds ratio=1.00) 
The fully adjusted model was adjusted for age, sex, systolic blood pressure, diabetes, fasting glucose, BMI, low density lipoprotein cholesterol, 
and smoking status. 
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